Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression

Clarke P. Anderson, Nino Keshelava, Noriko Satake, William H. Meek, C. Patrick Reynolds

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. Despite intensive-alkylator based regimens, >50% of patients with high-risk neuroblastoma (NB) die from recurrent disease that is probably due, in part, to acquired alkylator resistance. Procedure. Using buthionine sulfoximine (BSO)-mediated, glutathione (GSH) depletion to modulate melphalan (L-PAM) resistance, we examined six NB cell lines established after progressive disease following either standard chemotherapy, BSO/L-PAM therapy, or myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT). Results. Four of the six cell lines (three p53-nonfunctional and one p53-functional) showed high-level L-PAM resistance. Conclusions. Fixed ratio analysis demonstrated BSO/L-PAM synergy (combination index >1) for all cell lines tested, in L-PAM-resistant cell lines, the minimal cytotoxicity observed for BSO combined with nonmyeloablative concentrations of L-PAM was markedly enhanced (>4 logs total cell kill) when BSO was combined with myeloablative concentrations of L-PAM. In alkylator-resistant NB, the optimal use of BSO may require dose escalation of L-PAM to levels requiring AHSCT. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)659-662
Number of pages4
JournalMedical and Pediatric Oncology
Volume35
Issue number6
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Buthionine Sulfoximine
Melphalan
Neuroblastoma
Disease Progression
Cell Line
Alkylating Agents
Hematopoietic Stem Cells
Transplants
Glutathione
Drug Therapy

Keywords

  • Buthionine sulfoximine
  • Disease progression
  • Melphalan
  • Neuroblastoma cell lines
  • Synergism

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. / Anderson, Clarke P.; Keshelava, Nino; Satake, Noriko; Meek, William H.; Patrick Reynolds, C.

In: Medical and Pediatric Oncology, Vol. 35, No. 6, 2000, p. 659-662.

Research output: Contribution to journalArticle

Anderson, Clarke P. ; Keshelava, Nino ; Satake, Noriko ; Meek, William H. ; Patrick Reynolds, C. / Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. In: Medical and Pediatric Oncology. 2000 ; Vol. 35, No. 6. pp. 659-662.
@article{3c8f1de96a9c4423ba809664e9c63664,
title = "Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression",
abstract = "Background. Despite intensive-alkylator based regimens, >50{\%} of patients with high-risk neuroblastoma (NB) die from recurrent disease that is probably due, in part, to acquired alkylator resistance. Procedure. Using buthionine sulfoximine (BSO)-mediated, glutathione (GSH) depletion to modulate melphalan (L-PAM) resistance, we examined six NB cell lines established after progressive disease following either standard chemotherapy, BSO/L-PAM therapy, or myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT). Results. Four of the six cell lines (three p53-nonfunctional and one p53-functional) showed high-level L-PAM resistance. Conclusions. Fixed ratio analysis demonstrated BSO/L-PAM synergy (combination index >1) for all cell lines tested, in L-PAM-resistant cell lines, the minimal cytotoxicity observed for BSO combined with nonmyeloablative concentrations of L-PAM was markedly enhanced (>4 logs total cell kill) when BSO was combined with myeloablative concentrations of L-PAM. In alkylator-resistant NB, the optimal use of BSO may require dose escalation of L-PAM to levels requiring AHSCT. (C) 2000 Wiley-Liss, Inc.",
keywords = "Buthionine sulfoximine, Disease progression, Melphalan, Neuroblastoma cell lines, Synergism",
author = "Anderson, {Clarke P.} and Nino Keshelava and Noriko Satake and Meek, {William H.} and {Patrick Reynolds}, C.",
year = "2000",
doi = "10.1002/1096-911X(20001201)35:6<659::AID-MPO38>3.0.CO;2-4",
language = "English (US)",
volume = "35",
pages = "659--662",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression

AU - Anderson, Clarke P.

AU - Keshelava, Nino

AU - Satake, Noriko

AU - Meek, William H.

AU - Patrick Reynolds, C.

PY - 2000

Y1 - 2000

N2 - Background. Despite intensive-alkylator based regimens, >50% of patients with high-risk neuroblastoma (NB) die from recurrent disease that is probably due, in part, to acquired alkylator resistance. Procedure. Using buthionine sulfoximine (BSO)-mediated, glutathione (GSH) depletion to modulate melphalan (L-PAM) resistance, we examined six NB cell lines established after progressive disease following either standard chemotherapy, BSO/L-PAM therapy, or myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT). Results. Four of the six cell lines (three p53-nonfunctional and one p53-functional) showed high-level L-PAM resistance. Conclusions. Fixed ratio analysis demonstrated BSO/L-PAM synergy (combination index >1) for all cell lines tested, in L-PAM-resistant cell lines, the minimal cytotoxicity observed for BSO combined with nonmyeloablative concentrations of L-PAM was markedly enhanced (>4 logs total cell kill) when BSO was combined with myeloablative concentrations of L-PAM. In alkylator-resistant NB, the optimal use of BSO may require dose escalation of L-PAM to levels requiring AHSCT. (C) 2000 Wiley-Liss, Inc.

AB - Background. Despite intensive-alkylator based regimens, >50% of patients with high-risk neuroblastoma (NB) die from recurrent disease that is probably due, in part, to acquired alkylator resistance. Procedure. Using buthionine sulfoximine (BSO)-mediated, glutathione (GSH) depletion to modulate melphalan (L-PAM) resistance, we examined six NB cell lines established after progressive disease following either standard chemotherapy, BSO/L-PAM therapy, or myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT). Results. Four of the six cell lines (three p53-nonfunctional and one p53-functional) showed high-level L-PAM resistance. Conclusions. Fixed ratio analysis demonstrated BSO/L-PAM synergy (combination index >1) for all cell lines tested, in L-PAM-resistant cell lines, the minimal cytotoxicity observed for BSO combined with nonmyeloablative concentrations of L-PAM was markedly enhanced (>4 logs total cell kill) when BSO was combined with myeloablative concentrations of L-PAM. In alkylator-resistant NB, the optimal use of BSO may require dose escalation of L-PAM to levels requiring AHSCT. (C) 2000 Wiley-Liss, Inc.

KW - Buthionine sulfoximine

KW - Disease progression

KW - Melphalan

KW - Neuroblastoma cell lines

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=0033653618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033653618&partnerID=8YFLogxK

U2 - 10.1002/1096-911X(20001201)35:6<659::AID-MPO38>3.0.CO;2-4

DO - 10.1002/1096-911X(20001201)35:6<659::AID-MPO38>3.0.CO;2-4

M3 - Article

VL - 35

SP - 659

EP - 662

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -